CN102256617B - 膜联蛋白及其治疗炎性病症的用途 - Google Patents

膜联蛋白及其治疗炎性病症的用途 Download PDF

Info

Publication number
CN102256617B
CN102256617B CN200980150927.0A CN200980150927A CN102256617B CN 102256617 B CN102256617 B CN 102256617B CN 200980150927 A CN200980150927 A CN 200980150927A CN 102256617 B CN102256617 B CN 102256617B
Authority
CN
China
Prior art keywords
annexin
sepsis
tnf
lps
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980150927.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102256617A (zh
Inventor
冯清平
陆湘如
保罗·阿诺德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Health Sciences Centre Research Inc
Original Assignee
London Health Sciences Centre Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42106169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102256617(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by London Health Sciences Centre Research Inc filed Critical London Health Sciences Centre Research Inc
Publication of CN102256617A publication Critical patent/CN102256617A/zh
Application granted granted Critical
Publication of CN102256617B publication Critical patent/CN102256617B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980150927.0A 2008-10-17 2009-10-16 膜联蛋白及其治疗炎性病症的用途 Active CN102256617B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639008P 2008-10-17 2008-10-17
US61/106,390 2008-10-17
PCT/CA2009/001469 WO2010043045A1 (en) 2008-10-17 2009-10-16 Annexin and its use to treat inflammatory disorders

Publications (2)

Publication Number Publication Date
CN102256617A CN102256617A (zh) 2011-11-23
CN102256617B true CN102256617B (zh) 2015-04-08

Family

ID=42106169

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980150927.0A Active CN102256617B (zh) 2008-10-17 2009-10-16 膜联蛋白及其治疗炎性病症的用途

Country Status (6)

Country Link
US (1) US9192649B2 (enExample)
EP (1) EP2349321B1 (enExample)
JP (1) JP5590621B2 (enExample)
CN (1) CN102256617B (enExample)
CA (1) CA2740557C (enExample)
WO (1) WO2010043045A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
WO2010069605A2 (en) 2008-12-19 2010-06-24 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
HUE042929T2 (hu) * 2011-06-15 2019-07-29 Resother Pharma Aps Gyulladáscsökkentõ gyógyszerészeti termékek
IN2014DN07022A (enExample) * 2012-02-21 2015-04-10 Inst Nat Sante Rech Med
JP2015513535A (ja) 2012-02-21 2015-05-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ウイルス侵入補助因子としてのｔｉｍレセプター
WO2014077575A1 (ko) * 2012-11-13 2014-05-22 다인바이오 주식회사 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2019238550A1 (en) * 2018-06-12 2019-12-19 Universiteit Maastricht Method for the treatment of hypoxic-ischemic encephalopathy in newborns
CN109529017B (zh) * 2018-12-25 2022-06-14 江苏靶标生物医药研究所有限公司 一种膜联蛋白v的应用
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
US20220193192A1 (en) * 2019-08-30 2022-06-23 Suzhou Yabao Pharmaceutical R&D Co Ltd Methods of treating a traumatic brain injury
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
WO2022073134A1 (en) * 2020-10-09 2022-04-14 London Health Sciences Centre Research Inc. Annexin a5 compositions and methods
CN112618696B (zh) * 2020-12-14 2023-05-05 南京大学 Annexin A5在制备治疗胆汁淤积药物中的应用
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
CN117186239A (zh) * 2022-01-30 2023-12-08 南京瑞初医药有限公司 融合蛋白及其应用
CN118001375A (zh) * 2023-04-12 2024-05-10 上海萨美细胞技术有限公司 一种用于难愈性创面修复的药物
CN119097689A (zh) * 2023-06-08 2024-12-10 上海萨美细胞技术有限公司 一种用于治疗卵巢功能不全的药物
CN118001372A (zh) * 2023-07-04 2024-05-10 上海萨美细胞技术有限公司 膜联蛋白在抗衰老中的用途
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物
WO2025129329A1 (en) * 2023-12-23 2025-06-26 London Health Sciences Centre Research Inc. Methods for treatment of sepsis
CN118203650B (zh) * 2024-01-26 2025-04-29 上海萨丽斐生物科技有限公司 一种用于治疗色素沉着的药物
CN118846001B (zh) * 2024-07-09 2025-09-02 上海萨丽斐生物科技有限公司 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339285A3 (en) 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Recombinant endonexin ii
US5229367A (en) 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
CA2185535C (en) 1994-04-11 2000-10-24 Christiaan Peter Maria Reutelingsperger A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20030152513A1 (en) 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
JP4444821B2 (ja) 2002-06-06 2010-03-31 ツェ・チェイン・ウン 遺伝子組み換えによる新しい抗凝血性蛋白質
PT1755642E (pt) 2004-04-15 2010-04-20 Athera Biotechnologies Ab Anexina v para prevenção de aterotrombose e da ruptura de placas
WO2009001224A2 (en) 2007-06-22 2008-12-31 Eth Zurich Antivirals
WO2009018500A1 (en) * 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
PL2234631T3 (pl) 2007-12-18 2013-03-29 Athera Biotechnologies Ab Związki i metody stosowane w terapii choroby naczyniowej
HUE044621T2 (hu) * 2008-02-22 2019-11-28 Annexin Pharmaceuticals Ab Vegyületek és eljárások resztenózis megelõzésére vagy kezelésére
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general polulation;Cederholm等;《Ann.N.Y.acad.Sci.》;20070829;第1108卷(第1期);摘要、第98-100页 *
Inhibition of the interleukin-1β-induced pyresis in the rabbit by peptide 204-212 of lipocortin 5;Palmi等;《European journal of pharmacology》;19950701;第281卷(第1期);摘要、第98-99页 *
premature atherosclerotic cardiovascular disease in systemic lupus erythematosus;Westerweel等;《arthritis & rheumatism》;20070531;第56卷(第5期);第1384页左栏第1-10行 *
膜联蛋白A5与宫颈粘膜上皮细胞癌变的关系;李欣 等;《解剖学杂志》;20061231(第4期);433-435 *

Also Published As

Publication number Publication date
JP5590621B2 (ja) 2014-09-17
CN102256617A (zh) 2011-11-23
JP2012505837A (ja) 2012-03-08
US9192649B2 (en) 2015-11-24
EP2349321A1 (en) 2011-08-03
CA2740557C (en) 2020-04-14
US20120014920A1 (en) 2012-01-19
EP2349321B1 (en) 2020-04-22
CA2740557A1 (en) 2010-04-22
WO2010043045A1 (en) 2010-04-22
EP2349321A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
CN102256617B (zh) 膜联蛋白及其治疗炎性病症的用途
US20230036788A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Zicha et al. Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model
Konstandin et al. Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth
Chen et al. The E3 ubiquitin ligase WWP2 regulates pro-fibrogenic monocyte infiltration and activity in heart fibrosis
Creagh-Brown et al. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?
Camporeale et al. STAT3 activity is necessary and sufficient for the development of immune‐mediated myocarditis in mice and promotes progression to dilated cardiomyopathy
JP2023511358A (ja) 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子
Bär et al. Upregulation of embryonic transcription factors in right ventricular hypertrophy
Wang et al. Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase-and soluble guanylate cyclase-dependent mechanisms
JP5221959B2 (ja) 代謝障害の状態を治療するためのｉｌ−２２の使用
Ren et al. β3 Integrin deficiency promotes cardiac hypertrophy and inflammation
Zhang et al. Cardiac ankyrin repeat protein contributes to dilated cardiomyopathy and heart failure
CN106063928B (zh) 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
WO2012006585A2 (en) Use of interleukin-15 to treat cardiovascular diseases
CN102558357B (zh) 一种可以治疗心肌缺血再灌注损伤的p38α拮抗肽
Niizeki et al. Diacylglycerol kinase ζrescues Gαq-induced heart failure in transgenic mice
US20090169540A1 (en) Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy
WO2025167587A1 (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
AU2015374240B2 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production
Moellmann et al. Development of a mouse model of uremic cardiomyopathy: investigating the impact of chronic kidney disease on cardiac function and signaling pathway
Huang et al. The lymphocyte adapter protein: A negative regulator of myocardial ischemia/reperfusion injury
US20210244827A1 (en) Anc80 encoding sphingolipid-metabolizing proteins
Rainer et al. Cardiomyocyte-specific TGFβ suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction
Song et al. JAHA. 2021. pdf

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant